Gelesis obesity treatment studies well, but critics still wary; Flamel's once-a-week exenatide garners positive preclinical results;

> Gelesis released data this week showing that its obesity treatment was effective, but a critic at The New York Times panned the result as "modest." Story

> Flamel Technologies demonstrated positive results in a preclinical trial of once-a-week exenatide for Type 2 diabetes. Release

> A study that sheds light on the structure of milk during digestion could lead to the development of a new drug delivery technique. More

> New drug delivery company EastGate Acquisitions pulled in a research grant from Ontario Brain Institute. Release